Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.686556
Keywords
hereditary leiomyomatosis and renal cell carcinoma; fumarate hydratase; pathogenesis; mechanism; treatment
Categories
Funding
- National Natural Science Foundation of China [81660755]
- Science and Technology Project of Shenzhen of China [JCYJ20170307160524377]
Ask authors/readers for more resources
HLRCC is a rare hereditary cancer syndrome caused by mutations in the FH gene, with no standardized treatment currently available. The molecular mechanisms of how FH inactivation leads to HLRCC are discussed, along with potential therapeutic pharmacological strategies for prevention and treatment.
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare autosomal dominant hereditary cancer syndrome characterized by a predisposition to cutaneous leiomyomas, uterine leiomyomas, and renal cell carcinoma (RCC). It is known to be caused by germline mutations of the fumarate hydratase (FH) gene, which encodes an enzyme component of the citric acid cycle and catalyzes the conversion of fumarate to L-malate. Currently, there is no standardized treatment for HLRCC, which may be due in part to a lack of understanding of the underlying mechanisms. Here, the underlying molecular mechanisms by which the inactivation of FH causes HLRCC are discussed. Additionally, potential therapeutic pharmacological strategies are also summarized to provide new perspectives for the prevention and treatment of HLRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available